Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors

Author： Calcagno A.   Tettoni M. C.   Simiele M.   Trentini L.   Montrucchio C.   D'Avolio A.   Di Perri G.   Bonora S.  

Publisher： Oxford University Press

ISSN： 1460-2091

Source： Journal of Antimicrobial Chemotherapy, Vol.68, Iss.2, 2013-02, pp. : 482-484

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine

By Uy Jonathan   Yang Rong   Wirtz Victoria   Sheppard Louise   Farajallah Awny   McGrath Donnie  

AIDS Care, Vol. 23, Iss. 11, 2011-11 ,pp. : 1500-1504

Routledge Ltd

Access to resources Recommend Favorite

Reverse Transcriptase Inhibitors as Microbicides

By  

Current HIV Research, Vol. 10, Iss. 1, 2012-01 ,pp. : 27-35

Bentham Science Publishers

Access to resources Recommend Favorite

Direct, DNA Pol-γ-Independent Effects of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial Bioenergetics

By Lund Kaleb C.   Wallace Kendall B.  

Cardiovascular Toxicology, Vol. 4, Iss. 3, 2004-08 ,pp. : 217-228

Humana Press, Inc

Access to resources Recommend Favorite

The Use of Nucleoside Reverse Transcriptase Inhibitors Sparing Regimens in Treatment-Experienced HIV-1 Infected Patients

By  

Current HIV Research, Vol. 11, Iss. 3, 2013-04 ,pp. : 179-186

Bentham Science Publishers

Access to resources Recommend Favorite

Naringin Ameliorates HIV-1 Nucleoside Reverse Transcriptase Inhibitors- Induced Mitochondrial Toxicity

By  

Current HIV Research, Vol. 14, Iss. 6, 2016-12 ,pp. : 506-516

Bentham Science Publishers

Access to resources Recommend Favorite